Tired of being dumped by pharma partners, Vanderbilt’s neuroscience team takes a bold aim at the clinic
As the director of the Vanderbilt Center for Neuroscience Drug Discovery, Jeff Conn has specialized in preclinical development work on new drugs biopharma companies can take into the clinic. He’s also seen two of the big companies he’s partnered with — Bristol-Myers Squibb and AstraZeneca — make sudden, unexpected retreats from the field, which has known a steady diet of failures and setbacks in recent years.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
